Cullinan Therapeutics Inc (CGEM) Options Open Interest

Monitoring CGEM open interest helps you see where real money is positioned on Cullinan Therapeutics Inc's options and which strikes are attracting the most commitment from traders. Cullinan Therapeutics Inc's open interest reflects the total number of outstanding contracts that have not been closed or exercised, making it a powerful gauge of liquidity, conviction, and potential support and resistance zones. Use our scanner to monitor CGEM options open interest in real time and find the strikes that matter.

Open interest is distinct from volume: volume counts how many contracts are traded in a session, while open interest counts how many remain open at the end of the day. Rising CGEM options open interest alongside rising volume suggests new positions are being built, while falling open interest signals positions are being closed. Heavy open interest at specific strikes often acts as a magnet near expiration and can hint at where dealers and large traders expect Cullinan Therapeutics Inc to settle.

Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.

Pin risk into expiration, dealer positioning, liquidity checks for large orders — all of it starts with knowing where CGEM open interest is concentrated. Our scanner maps Cullinan Therapeutics Inc's open interest across every strike and expiry, flags unusual buildups, and lets you drill into the contracts that institutional money is actually holding. Trade Cullinan Therapeutics Inc's options open interest as the signal it is, not as an afterthought.